文献速递消化系统肿瘤

肝细胞癌相关新抗原诱导特异性CD8(+)T细胞的研究

[Induction of specific CD8(+) T cells against hepatocellular carcinoma-associated neoantigens].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2019-01-01

该研究通过全基因组和外显子测序分析肝细胞癌(HCC)体细胞突变,预测TP53和LAMA3突变相关新抗原表位并合成多肽,诱导特异性CD8(+)细胞毒性T淋巴细胞(CTL)。结果显示TP53突变率约40%、LAMA3约8%,两者在肿瘤组织中表达均高于正常组织,诱导的CTL对负载突变肽的靶细胞有特异性杀伤作用,对正常细胞无杀伤作用。

要点

  • HCC组织中TP53突变率约40%,LAMA3突变率约8%。
  • TP53和LAMA3在肿瘤组织中表达均高于配对正常组织(P<0.05)。
  • 预测突变肽诱导的CTL特异性杀伤负载突变抗原的靶细胞,不杀伤正常细胞。

核心结论

  • TP53和LAMA3在HCC组织中存在较高突变频率且表达高于正常组织。
  • 带有突变位点的肿瘤新抗原多肽所诱导的CTL对表达该抗原的靶细胞有特异性杀伤作用,对正常细胞无杀伤作用。

研究设计与样本

  • 分析HCC患者肿瘤组织及配对正常组织的全基因组和外显子测序数据以寻找体细胞突变。
  • 结合患者HLA表型,用NetMHC软件预测高结合力突变表位并合成多肽。
  • 在GEO数据库GSE25097(GPL10687平台)中比较突变基因在肝癌和正常组织的表达差异。
  • 用实时荧光定量PCR和免疫组化在10例HCC患者的肿瘤和配对癌旁正常组织中验证表达。
  • 用预测的突变位点多肽诱导特异性CTL并检测其对负载相应抗原靶细胞的杀伤效果。

主要发现

  • 测序的HCC组织中TP53突变率约为40%,LAMA3突变率约为8%。
  • GSE25097数据库中肿瘤组织TP53 mRNA相对表达量为1.57±0.02、LAMA3为1.37±0.10,均高于正常组织(分别为0.54±0.01和0.36±0.01,均P<0.05)。
  • 10例HCC组织中肿瘤TP53 mRNA相对表达量为0.24±0.03,高于癌旁组织(0.11±0.01,P<0.05);LAMA3 mRNA为0.13±0.06,高于癌旁组织(0.01±0.01,P<0.05)。
  • 免疫组化检测TP53和LAMA3蛋白表达结果与实时荧光定量PCR结果一致。
  • 中国人群MHC-Ⅰ基因亚型统计显示HLA-A2、HLA-A11或HLA-A24三者所占比例高达70%。

关键数值与推荐

  • TP53在HCC组织中突变率约为40%,LAMA3约为8%。
  • GSE25097数据库中肿瘤TP53 mRNA为1.57±0.02、LAMA3为1.37±0.10,正常组织分别为0.54±0.01和0.36±0.01,均P<0.05。
  • 10例HCC组织中肿瘤TP53 mRNA为0.24±0.03、LAMA3为0.13±0.06,癌旁组织分别为0.11±0.01和0.01±0.01,均P<0.05。
  • 中国人群HLA-A2、HLA-A11或HLA-A24三者所占比例高达70%。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To predict the tumor neoantigen peptides in hepatocellular carcinoma (HCC), and examine their specific immune effects against the tumor cells without injury to normal cells. Methods: The data of whole-genome sequencing and exome sequencing of HCC tumor and matched non-tumor liver tissues were analyzed to confirm the HCC-associated somatic mutations. Based on the HLA phenotype of the patients, we used NetMHC software to predict the neoantigen epitopes with high binding affinity to their MHC-I molecules. The predicted peptides with mutation sites included were synthesized. GPL10687 platform was applied to examine the gene expression difference between tumor and normal tissues of the selected genes in GSE25097, one of the GEO databases. The quantitative real-time PCR (qRT-qPCR) and immunohistochemistry were used to confirm the expressions in tumors and normal tissues of the selected genes. By using the predicted peptides, we induced the generation of antigen-specific CD8(+) cytotoxic T lymphocytes (CTLs) and examined their specific effects against tumor cells. Results: The mutation frequency of TP53 (tumor protein p53) was 40%, and LAMA3 (Laminin Subunit Alpha 3) was 8% in the analyzed HCC tissues. In GSE25097 database, TP53 and LAMA3 mRNA levels in tumors were 1.57±0.02 and 1.37±0.10, which were significantly increased than those in matched no-tumor tissue (0.54±0.01 and 0.36±0.01, P<0.05). The differences of expression levels of TP53 and LAMA3 in tumor and no-tumor tissues were validated by using qRT-qPCR and immunohistochemistry in 10 HCC tissues. The mRNA levels of TP53 and LAMA3 in tumors were 0.24±0.03 and 0.13±0.06, which were significantly elevated than those in matched no-tumor tissue (0.11±0.01 and 0.01±0.01, P<0.05). Among the Chinese population, HLA-A2 and HLA-A11 and HLA-A24 accounted for 70%, representing the major MHC-I molecules. The CTLs induced by predicted peptides showed cytotoxicity to the targets pulsed with mutated peptide, with no effect on the target pulsed with normal peptide and on normal cells. Conclusions: TP53 and LAMA3 existed relative higher mutation frequency in HCC, and expressed higher in tumor tissues. The induced CTLs by predicted peptides derived from mutation-associated protein could specific kill the target cells without injury to normal cells. 目的: 寻找肝细胞癌(HCC)突变相关肿瘤新抗原,确定其诱导产生的细胞毒性T淋巴细胞(CTL)可特异性作用于肿瘤细胞,为进行HCC的疫苗免疫治疗提供理论依据。 方法: 分析HCC患者肿瘤组织及其配对的正常组织全基因组和外显子测序数据,寻找肿瘤相关体细胞突变,结合患者人类白细胞抗原(HLA)表型,利用NetMHC软件预测具有较高结合力的突变表位,由此合成相应的多肽。在GEO数据库中选取GSE25097,利用GPL10687平台统计突变基因在肝癌组织和正常组织中的表达差异。采用实时荧光定量PCR法和免疫组化染色,检测10例HCC患者的肿瘤组织和配对癌旁正常组织中相关基因及其蛋白的表达差异。采用预测的带有突变位点的肿瘤新抗原合成多肽,诱导特异性CTL,检测其对负载有相应抗原的肿瘤细胞的杀伤效果。 结果: 在全基因组和外显子测序的HCC组织中,TP53的突变率约为40%,LAMA3的突变率约为8%。在GSE25097数据库中,TP53和LAMA3 mRNA在肿瘤组织中的相对表达量分别为1.57±0.02和1.37±0.10,均高于正常组织(分别为0.54±0.01和0.36±0.01,均P<0.05)。实时荧光定量PCR法检测结果显示,TP53 mRNA在肿瘤组织中的相对表达量为0.24±0.03,明显高于癌旁组织(0.11±0.01,P<0.05);LAMA3 mRNA在肿瘤组织中的相对表达量为0.13±0.06,明显高于癌旁组织(0.01±0.01,P<0.05)。免疫组化染色检测TP53和LAMA3蛋白的表达情况,与实时荧光定量PCR检测结果一致。对中国人群Ⅰ型主要组织相容性抗原(MHC-Ⅰ)基因亚型的统计结果显示,HLA-A2、HLA-A11或HLA-A24三者所占比列高达70%。预测的带有TP53和LAMA3突变位点的肿瘤新抗原多肽所诱导的CTL对负载有相应抗原的靶细胞具有显著杀伤作用,但不具有杀伤负载同一肽段带有正常非突变抗原的靶细胞,对机体正常细胞无杀伤作用。 结论: TP53和LAMA3在HCC组织中存在高突变,并且其表达高于正常组织。带有突变位点的肿瘤新抗原多肽所诱导产生的CTL,对表达有该抗原的靶细胞具有特异性杀伤作用,但不影响机体正常细胞。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang YM, Zhao BH, Chen K, et al. [Induction of specific CD8(+) T cells against hepatocellular carcinoma-associated neoantigens]. Zhonghua Zhong Liu Za Zhi. 2019. PMID: 31216828. doi:10.3760/cma.j.issn.0253-3766.2019.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。